Author

James P. Nezamis

Observed names: J. Nezamis, JAMES NEZAMIS, James Nezamis

Observed institutions: Mount Sinai Beth Israel, IQVIA (United States), Insmed (United States), Epix Pharmaceuticals (United States), Adare Pharma Solutions (United States), Kempenhaeghe

OpenAlex ID: A5028059182

Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study

2018 · David E. Griffith, Gina Eagle, et al. · American Journal of Respiratory and Critical Care Medicine · 362

Effects of felbamate on the pharmacokinetics of phenobarbital

1995 · Pascale Reidenberg, Paul Glue, et al. · Clinical Pharmacology & Therapeutics · 60

Fluticasone Propionate Orally Disintegrating Tablet (APT-1011) for Eosinophilic Esophagitis: Randomized Controlled Trial

2022 · Evan S. Dellon, Alfredo J. Lucendo, et al. · Clinical Gastroenterology and Hepatology · 53

PDF

Diffusing capacity and forced vital capacity in 5,003 asbestos‐exposed workers: Relationships to interstitial fibrosis (ILO profusion score) and pleural thickening

2013 · Albert Miller, Raphael Warshaw, et al. · American Journal of Industrial Medicine · 26

Effects of felbamate on the pharmacokinetics of the monohydroxy and dihydroxy metabolites of oxcarbazepine

1995 · Jacques A.R.J. Hulsman, Theo W. Rentmeester, et al. · Clinical Pharmacology & Therapeutics · 25

Effect of Alosetron on the Pharmacokinetics of Alprazolam

2001 · Doreen L. D'Souza, Laurence M. Levasseur, et al. · The Journal of Clinical Pharmacology · 19

Effect of Alosetron on the Pharmacokinetics of Fluoxetine

2001 · Doreen L. D'Souza, Dan C. Dimmitt, et al. · The Journal of Clinical Pharmacology · 16

Randomized Phase 3 Trial of Amikacin Liposome Inhalation Suspension (ALIS) for Treatment-Refractory Nontuberculous Mycobacterial (NTM) Lung Disease Caused by Mycobacterium Avium Complex (MAC) in Adult Patients

2018 · David E. Griffith, Gina Eagle, et al. · American Journal of Respiratory and Critical Care Medicine · 6

Sustainability and Durability of Culture Conversion in Patients Receiving Amikacin Liposome Inhalation Suspension (ALIS) for Treatment-Refractory Mycobacterium Avium Complex Lung Disease (MAC-LD) in the CONVERT Study

2019 · D.E. Griffith, R. Thomson, et al. · 4

Durability of culture conversion in patients receiving Amikacin Liposome Inhalation Suspension (ALIS) for treatment-refractory Mycobacterium avium complex lung disease (MAC-LD) in the CONVERT study

2019 · David E. Griffith, Rachel Thomson, et al. · European Respiratory Journal · 3

Extension Study of Amikacin Liposome Inhalation Suspension (alis) for Treatment-refractory Lung Disease Caused by Mycobacterium Avium Complex (mac)

2018 · KEVIN WINTHROP, GINA EAGLE, et al. · CHEST Journal · 3

S0345 Safety and Efficacy of Long-Term Treatment of EoE With Fluticasone Propionate Orally Disintegrating Tablet (APT-1011): Results From 40 Weeks Treatment in a Phase 2b Randomized Double-Blind Placebo-Controlled Trial

2020 · Evan S. Dellon, Alfredo Lucendo, et al. · The American Journal of Gastroenterology · 2

Mo1184 AN EPISODE-BASED PATIENT-REPORTED OUTCOME MEASURE OF DYSPHAGIA EXPERIENCE IS FEASIBLE AND NOT BURDENSOME FOR PATIENTS WITH EOSINOPHILIC ESOPHAGITIS

2020 · Evan S. Dellon, Nicole Sparling, et al. · Gastroenterology · 2

S458 Patient-Reported Symptom Improvement Following Treatment With APT-1011 in Patients with Eosinophilic Esophagitis as Measured by the PROSE: Results from FLUTE, A Phase 2b Clinical Trial

2021 · Ralph Turner, Jeffrey M. Rohay, et al. · The American Journal of Gastroenterology · 1

540 Fluticasone Propionate Orally Disintegrating Tablet (apt-1011) Improves Histologic, Endoscopic and Symptomatic Responses in Eosinophilic Esophagitis Patients With Fibro-stenotic Features: Results From a Phase 2b Trial

2021 · Evan S. Dellon, Gary W. Falk, et al. · Gastroenterology · 1

Mo1182 AN EPISODE-BASED, PATIENT-REPORTED OUTCOME MEASURE OF DYSPHAGIA ACCURATELY CAPTURES RESPONSE TO TREATMENT WITH APT-1011 IN A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRIAL IN ADULTS WITH EOSINOPHILIC ESOPHAGITIS

2020 · Evan S. Dellon, Gary W. Falk, et al. · Gastroenterology · 1

Six-Minute Walk Test (6MWT) Performance in Adult Patients Receiving Amikacin Liposome Inhalation Suspension (ALIS) for Treatment-Refractory Nontuberculous Mycobacterial (NTM) Lung Disease Caused by Mycobacterium Avium Complex (MAC)

2018 · Kevin Winthrop, Gina Eagle, et al. · American Journal of Respiratory and Critical Care Medicine · 1

965 Fluticasone Propionate Oral Disintegrating Tablet, Apt-1011, Leads to a Greater Complete Symptomatic Response Rate Compared to Placebo in Subjects With Eosinophilic Esophagitis (eoe)

2024 · Evan S. Dellon, Gary W. Falk, et al. · Gastroenterology

964 Fluticasone Proprionate Oral Disintegrating Tablet, Apt-1011, Improves Fibrostenotic Features of Strictures and Grade 2/3 Rings in Subjects With Eosinophilic Esophagitis (eoe)

2024 · Evan S. Dellon, Gary W. Falk, et al. · Gastroenterology

S465 Development and Content Validity of the PROSE Daily Diary to Measure Dysphagia Episodes in Adults and Adolescents With Eosinophilic Esophagitis

2021 · Evan S. Dellon, Stella Karantzoulis, et al. · The American Journal of Gastroenterology

S353 Time to Clinically Meaningful Improvement in Dysphagia Frequency in Adults with Eosinophilic Esophagitis: A Post-Hoc Analysis From a Phase 2b Trial of APT-1011, a Fluticasone Propionate Oral Disintegrating Tablet

2021 · Gary Falk, Ikuo Hirano, et al. · The American Journal of Gastroenterology

Fr172 LOW RATES OF GLUCOCORTICOID-RELATED ADVERSE EFFECTS WITH LONG-TERM TREATMENT OF EOSINOPHILIC ESOPHAGITIS WITH FLUTICASONE PROPIONATE ORALLY DISINTEGRATING TABLET (APT-1011): RESULTS FROM 52 WEEKS OF EXPOSURE IN A PHASE 2B TRIAL.

2021 · Evan S. Dellon, Gary W. Falk, et al. · Gastroenterology

Works count: 22

Citation count: 585

H-index: 7

I10-index: 7